Treating Patients Who Are Unresponsive to Therapy
Addressing Nonadherence to Therapy
How Epilepsy Treatment Efficacy Is Determined
Anticonvulsants to Treat Epilepsy and Alternatives
The Classification of Epilepsy and Seizures
Epilepsy Case Presentation and Diagnostic Process
Real-World Practice: Perampanel for Partial-Onset Seizures
A Treatment Option for Uncontrolled Partial-Onset Seizures
How Treatment Efficacy Is Determined
Antiepileptic Therapy Adverse Effects and Nonadherence
Antiepileptic Therapy Half-Life, Dosing & Black Box Warning
Seizure Classification and Goals of Therapy
Epilepsy Prevalence and Therapy Resistance
A 55-Year-Old Woman With Epilepsy
White Paper Calls for Global Adoption of Mechanical Thrombectomy
The Mission Thrombectomy 2020+ group outlined a plan to increase the awareness, accessibility, and action for mechanical thrombectomy utilization for patients with stroke globally.
Sesquient Approved for Treatment of Status Epilepticus in Adults, Children
The drug joins Cerebryx as the second FDA-approved fosphenytoin for benzodiazepine-refractory status epilepticus.
Recommendations Published for Myasthenia Gravis Management
New recommendations were developed for the use of rituximab, eculizumab, and methotrexate, as well as updates on previous recommendations for thymectomy.
Jacqueline French, MD: Identifying Focal Epilepsy Seizures
The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the groundwork done with the Human Epilepsy Project for a recent analysis.
COVID-19 Diagnosis at Stroke Onset Linked to Worse Outcomes
An analysis from English and Scottish stroke centers provides physicians a new view of the trends and outcomes of patients with COVID-19 who experience stroke.
Virendra Mishra, PhD: Previous Data on Parkinson Disease Dementia
The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.
This Week on NeurologyLive
Here's what is coming soon to NeurologyLive.
Very Early Mobilization Increases Mortality for Patients Within 14 Days Post-Stroke
A tertiary analysis of the AVERT study reveals divergent findings suggesting that mortality increases with VEM compared to usual care after restricting follow-up to 14 days.
Raman Malhotra, MD: Highlights From Sleep 2020
The associate professor of neurology at Washington University in St. Louis detailed a number of key presentations on advances and novel medications in the sleep space.
Veronica Hood, PhD: New ICD-10 Codes for Dravet Syndrome
The research coordinator of the Dravet Foundation provided background on the new ICD-10 codes announced for Dravet syndrome and how they came about.
SARS-CoV-2 May Alter Blood-Brain Barrier Function
There is no evidence yet that SARS-CoV-2 can pass the blood-brain barrier, though its effects on the barrier may be intensified in those with dementia.
PD GENEration Receives Additional Funding, Continuous Ocrelizumab Effective in Progressive MS, Guidelines for Down Syndrome Published
Neurology News Network for the week ending November 7, 2020.
Aducanumab Approval Not Recommended by FDA Advisory Committee
Biogen’s investigational Alzheimer disease treatment is currently under review with a Prescription Drug User Fee Act target action date of March 7, 2021, if not earlier.
NeurologyLive Friday 5 — November 6, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.
Pavel Klein, MD: Initiating Conversations on Changing Treatment Strategy
The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, described the challenges he’s faced when having to discuss a change in treatment strategies with his patients.
Ticagrelor Approved for Recurrent Stroke Prevention
The decision was based on findings from the phase 3 THALES trial, which showed aspirin plus ticagrelor significantly reduced stroke and death compared with aspirin alone in patients with acute ischemic stroke or TIA.
